Verastem Oncology’s pancreatic cancer combo shows 86% OS rate

Verastem’s data of its pancreatic cancer combo follows Revolution’s impressive daraxonrasib readout at ASCO 2026. Verastem’s data in pancreatic cancer follows Revolution’s impressive daraxonrasib readout at ASCO 2026. Pancreatic cancer has seen very few significant advances for some time, until an ASCO 2026 announcement. Credit: Jo Panuwat D / Shutterstock.com Verastem Oncology’s pancreatic cancer combination has shown an 86% overall survival (OS) rate in a Phase Ib/IIa trial. In the RAMP 205 study (NCT05669482), 29 patients were enrolled into the recommended Phase II dose cohort, which evaluated Avmapki Fakzynja (avutometinib plus defactinib) in combination with gemcitabine and nab-paclitaxel in first-line…

Source: Clinical Trials Arena